Nautilus Biotechnology (NAUT) Competitors

$2.86 -0.03 (-1.04%)

Closing price 04:00 PM Eastern

Extended Trading

$2.94 +0.08 (+2.80%)

As of 07:10 PM Eastern

NAUT vs. ALNT, EYPT, TRNS, CTKB, and FEIM

Should you be buying Nautilus Biotechnology stock or one of its competitors? The main competitors of Nautilus Biotechnology include Allient (ALNT), Eyepoint Pharmaceuticals (EYPT), Transcat (TRNS), Cytek Biosciences (CTKB), and Frequency Electronics (FEIM). These companies are all part of the "measuring and control equipment" industry.

How does Nautilus Biotechnology compare to Allient?

Allient (NASDAQ:ALNT) and Nautilus Biotechnology (NASDAQ:NAUT) are both small-cap measuring and control equipment companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.

: Allient has a net margin of 3.97% compared to Nautilus Biotechnology's net margin of 0.00%. Allient's return on equity of 12.53% beat Nautilus Biotechnology's return on equity.
Company Net Margins Return on Equity Return on Assets
Allient 3.97% 12.53% 6.21%
Nautilus Biotechnology N/A -35.04% -29.16%
: Allient has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500. Comparatively, Nautilus Biotechnology has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500.
: 61.6% of Allient shares are held by institutional investors. Comparatively, 50.7% of Nautilus Biotechnology shares are held by institutional investors. 15.0% of Allient shares are held by company insiders. Comparatively, 41.1% of Nautilus Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
: In the previous week, Allient had 6 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 7 mentions for Allient and 1 mentions for Nautilus Biotechnology. Allient's average media sentiment score of 0.64 beat Nautilus Biotechnology's score of 0.64 indicating that Allient is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Allient
3 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Nautilus Biotechnology
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Allient has higher revenue and earnings than Nautilus Biotechnology. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Allient, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Allient $554.48M 2.39 $22.03M $1.32 59.09
Nautilus Biotechnology N/A N/A -$59M -$0.46 N/A
: Allient currently has a consensus price target of $70.75, suggesting a potential downside of 9.29%. Nautilus Biotechnology has a consensus price target of $4.00, suggesting a potential upside of 39.86%. Given Nautilus Biotechnology's higher possible upside, analysts clearly believe Nautilus Biotechnology is more favorable than Allient.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Allient
0 Sell rating(s)
3 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.50
Nautilus Biotechnology
1 Sell rating(s)

0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00

Company	Net Margins	Return on Equity	Return on Assets
Allient	3.97%	12.53%	6.21%
Nautilus Biotechnology	N/A	-35.04%	-29.16%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allient	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nautilus Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allient	$554.48M	2.39	$22.03M	$1.32	59.09
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.46	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allient	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Allient beats Nautilus Biotechnology on 13 of the 15 factors compared between the two stocks.

How does Nautilus Biotechnology compare to Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Nautilus Biotechnology (NASDAQ:NAUT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

: 99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. Comparatively, 50.7% of Nautilus Biotechnology shares are owned by institutional investors. 4.5% of Eyepoint Pharmaceuticals shares are owned by company insiders. Comparatively, 41.1% of Nautilus Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
: Nautilus Biotechnology has lower revenue, but higher earnings than Eyepoint Pharmaceuticals. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Eyepoint Pharmaceuticals $31.37M 36.73 -$231.96M -$3.16 N/A
Nautilus Biotechnology N/A N/A -$59M -$0.46 N/A
: Eyepoint Pharmaceuticals presently has a consensus price target of $32.20, indicating a potential upside of 134.18%. Nautilus Biotechnology has a consensus price target of $4.00, indicating a potential upside of 39.86%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Nautilus Biotechnology.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eyepoint Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)

5 Buy rating(s)

2 Strong Buy rating(s)
3.00
Nautilus Biotechnology
1 Sell rating(s)

0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: Nautilus Biotechnology has a net margin of 0.00% compared to Eyepoint Pharmaceuticals' net margin of -739.39%. Nautilus Biotechnology's return on equity of -35.04% beat Eyepoint Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Eyepoint Pharmaceuticals -739.39% -88.31% -72.52%
Nautilus Biotechnology N/A -35.04% -29.16%
: Eyepoint Pharmaceuticals has a beta of 1.76, meaning that its stock price is 76% more volatile than the S&P 500. Comparatively, Nautilus Biotechnology has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500.
: In the previous week, Eyepoint Pharmaceuticals had 3 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 4 mentions for Eyepoint Pharmaceuticals and 1 mentions for Nautilus Biotechnology. Nautilus Biotechnology's average media sentiment score of 0.64 beat Eyepoint Pharmaceuticals' score of 0.26 indicating that Nautilus Biotechnology is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Eyepoint Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Nautilus Biotechnology
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$31.37M	36.73	-$231.96M	-$3.16	N/A
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.46	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-739.39%	-88.31%	-72.52%
Nautilus Biotechnology	N/A	-35.04%	-29.16%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eyepoint Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nautilus Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Eyepoint Pharmaceuticals beats Nautilus Biotechnology on 9 of the 16 factors compared between the two stocks.

How does Nautilus Biotechnology compare to Transcat?

Nautilus Biotechnology (NASDAQ:NAUT) and Transcat (NASDAQ:TRNS) are both small-cap measuring and control equipment companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.

: Transcat has a net margin of 2.47% compared to Nautilus Biotechnology's net margin of 0.00%. Transcat's return on equity of 6.15% beat Nautilus Biotechnology's return on equity.
Company Net Margins Return on Equity Return on Assets
Nautilus Biotechnology N/A -35.04% -29.16%
Transcat 2.47% 6.15% 4.15%
: Nautilus Biotechnology has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500. Comparatively, Transcat has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500.
: Nautilus Biotechnology presently has a consensus price target of $4.00, indicating a potential upside of 39.86%. Transcat has a consensus price target of $105.33, indicating a potential upside of 39.83%. Given Nautilus Biotechnology's higher possible upside, research analysts plainly believe Nautilus Biotechnology is more favorable than Transcat.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nautilus Biotechnology
1 Sell rating(s)
0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Transcat
2 Sell rating(s)

0 Hold rating(s)

2 Buy rating(s)

1 Strong Buy rating(s)
2.40
: 50.7% of Nautilus Biotechnology shares are owned by institutional investors. Comparatively, 98.3% of Transcat shares are owned by institutional investors. 41.1% of Nautilus Biotechnology shares are owned by insiders. Comparatively, 2.8% of Transcat shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
: Transcat has higher revenue and earnings than Nautilus Biotechnology. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Nautilus Biotechnology N/A N/A -$59M -$0.46 N/A
Transcat $319.69M 2.20 $14.52M $0.85 88.62
: In the previous week, Transcat had 1 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 2 mentions for Transcat and 1 mentions for Nautilus Biotechnology. Transcat's average media sentiment score of 1.30 beat Nautilus Biotechnology's score of 0.64 indicating that Transcat is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nautilus Biotechnology
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Transcat
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Company	Net Margins	Return on Equity	Return on Assets
Nautilus Biotechnology	N/A	-35.04%	-29.16%
Transcat	2.47%	6.15%	4.15%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Transcat	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.40

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.46	N/A
Transcat	$319.69M	2.20	$14.52M	$0.85	88.62

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nautilus Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Transcat	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Transcat beats Nautilus Biotechnology on 13 of the 16 factors compared between the two stocks.

How does Nautilus Biotechnology compare to Cytek Biosciences?

Cytek Biosciences (NASDAQ:CTKB) and Nautilus Biotechnology (NASDAQ:NAUT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.

: 69.5% of Cytek Biosciences shares are held by institutional investors. Comparatively, 50.7% of Nautilus Biotechnology shares are held by institutional investors. 10.3% of Cytek Biosciences shares are held by company insiders. Comparatively, 41.1% of Nautilus Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
: Cytek Biosciences has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500. Comparatively, Nautilus Biotechnology has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500.
: Nautilus Biotechnology has a net margin of 0.00% compared to Cytek Biosciences' net margin of -33.02%. Cytek Biosciences' return on equity of -7.70% beat Nautilus Biotechnology's return on equity.
Company Net Margins Return on Equity Return on Assets
Cytek Biosciences -33.02% -7.70% -5.89%
Nautilus Biotechnology N/A -35.04% -29.16%
: Nautilus Biotechnology has lower revenue, but higher earnings than Cytek Biosciences. Cytek Biosciences is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cytek Biosciences $201.49M 3.06 -$66.54M -$0.51 N/A
Nautilus Biotechnology N/A N/A -$59M -$0.46 N/A
: Cytek Biosciences currently has a consensus price target of $5.38, indicating a potential upside of 12.45%. Nautilus Biotechnology has a consensus price target of $4.00, indicating a potential upside of 39.86%. Given Nautilus Biotechnology's higher probable upside, analysts plainly believe Nautilus Biotechnology is more favorable than Cytek Biosciences.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cytek Biosciences
2 Sell rating(s)
2 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.00
Nautilus Biotechnology
1 Sell rating(s)

0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: In the previous week, Cytek Biosciences and Cytek Biosciences both had 1 articles in the media. Nautilus Biotechnology's average media sentiment score of 0.64 beat Cytek Biosciences' score of 0.00 indicating that Nautilus Biotechnology is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cytek Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Nautilus Biotechnology
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Company	Net Margins	Return on Equity	Return on Assets
Cytek Biosciences	-33.02%	-7.70%	-5.89%
Nautilus Biotechnology	N/A	-35.04%	-29.16%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytek Biosciences	$201.49M	3.06	-$66.54M	-$0.51	N/A
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.46	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytek Biosciences	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytek Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nautilus Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Nautilus Biotechnology beats Cytek Biosciences on 7 of the 13 factors compared between the two stocks.

How does Nautilus Biotechnology compare to Frequency Electronics?

Nautilus Biotechnology (NASDAQ:NAUT) and Frequency Electronics (NASDAQ:FEIM) are both small-cap measuring and control equipment companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

: Frequency Electronics has higher revenue and earnings than Nautilus Biotechnology. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Frequency Electronics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Nautilus Biotechnology N/A N/A -$59M -$0.46 N/A
Frequency Electronics $67.82M 8.16 $23.69M $0.75 74.96
: In the previous week, Frequency Electronics had 5 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 6 mentions for Frequency Electronics and 1 mentions for Nautilus Biotechnology. Frequency Electronics' average media sentiment score of 0.66 beat Nautilus Biotechnology's score of 0.64 indicating that Frequency Electronics is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nautilus Biotechnology
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Frequency Electronics
2 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Nautilus Biotechnology has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Comparatively, Frequency Electronics has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500.
: Nautilus Biotechnology presently has a consensus price target of $4.00, indicating a potential upside of 39.86%. Frequency Electronics has a consensus price target of $43.67, indicating a potential downside of 22.33%. Given Nautilus Biotechnology's higher possible upside, equities analysts plainly believe Nautilus Biotechnology is more favorable than Frequency Electronics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nautilus Biotechnology
1 Sell rating(s)
0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Frequency Electronics
0 Sell rating(s)

1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.50
: 50.7% of Nautilus Biotechnology shares are owned by institutional investors. Comparatively, 58.6% of Frequency Electronics shares are owned by institutional investors. 41.1% of Nautilus Biotechnology shares are owned by insiders. Comparatively, 28.0% of Frequency Electronics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
: Frequency Electronics has a net margin of 10.78% compared to Nautilus Biotechnology's net margin of 0.00%. Frequency Electronics' return on equity of 12.69% beat Nautilus Biotechnology's return on equity.
Company Net Margins Return on Equity Return on Assets
Nautilus Biotechnology N/A -35.04% -29.16%
Frequency Electronics 10.78% 12.69% 7.84%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.46	N/A
Frequency Electronics	$67.82M	8.16	$23.69M	$0.75	74.96

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nautilus Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Frequency Electronics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Frequency Electronics	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Company	Net Margins	Return on Equity	Return on Assets
Nautilus Biotechnology	N/A	-35.04%	-29.16%
Frequency Electronics	10.78%	12.69%	7.84%

Summary

Frequency Electronics beats Nautilus Biotechnology on 11 of the 14 factors compared between the two stocks.

Get Nautilus Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NAUT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NAUT vs. The Competition

Export

Metric	Nautilus Biotechnology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$363.45M	$3.39B	$6.24B	$11.86B
Dividend Yield	N/A	2.20%	2.73%	5.21%
P/E Ratio	-6.22	38.85	29.04	28.48
Price / Sales	N/A	157.28	477.10	60.43
Price / Cash	N/A	57.88	27.62	36.52
Price / Book	2.31	7.03	9.67	6.67
Net Income	-$59M	$23.62M	$3.55B	$332.64M
7 Day Performance	10.42%	3.67%	1.70%	2.01%
1 Month Performance	-13.60%	7.17%	5.62%	9.19%
1 Year Performance	317.40%	67.04%	34.42%	39.59%

Nautilus Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NAUT Nautilus Biotechnology	3.916 of 5 stars	$2.86 -1.0%	$4.00 +39.9%	N/A	$363.45M	N/A	N/A	130	Earnings Report
ALNT Allient	2.4896 of 5 stars	$74.33 +0.2%	$63.60 -14.4%	N/A	$1.26B	$554.48M	56.31	2,478	News Coverage Upcoming Earnings Gap Up
EYPT Eyepoint Pharmaceuticals	2.6561 of 5 stars	$13.47 -1.0%	$32.20 +139.0%	N/A	$1.13B	$31.37M	N/A	120	Positive News Upcoming Earnings
TRNS Transcat	2.2677 of 5 stars	$75.68 -2.1%	$105.33 +39.2%	N/A	$721.28M	$278.42M	89.04	1,245	Positive News
CTKB Cytek Biosciences	0.7505 of 5 stars	$4.57 +2.5%	$5.38 +17.6%	N/A	$570.28M	$201.49M	N/A	500	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NAUT) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nautilus Biotechnology (NAUT) Competitors

NAUT vs. ALNT, EYPT, TRNS, CTKB, and FEIM

How does Nautilus Biotechnology compare to Allient?

Summary

How does Nautilus Biotechnology compare to Eyepoint Pharmaceuticals?

Summary

How does Nautilus Biotechnology compare to Transcat?

Summary

How does Nautilus Biotechnology compare to Cytek Biosciences?

Summary

How does Nautilus Biotechnology compare to Frequency Electronics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAUT vs. The Competition

Nautilus Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nautilus Biotechnology (NAUT) Competitors

NAUT vs. ALNT, EYPT, TRNS, CTKB, and FEIM

How does Nautilus Biotechnology compare to Allient?

Summary

How does Nautilus Biotechnology compare to Eyepoint Pharmaceuticals?

Summary

How does Nautilus Biotechnology compare to Transcat?

Summary

How does Nautilus Biotechnology compare to Cytek Biosciences?

Summary

How does Nautilus Biotechnology compare to Frequency Electronics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAUT vs. The Competition

Nautilus Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools